Albuminuria as a Vital Sign: Why Urine ACR Is Becoming Central to Kidney-Cardiovascular Risk Assessment

Introduction

For many years, serum creatinine and estimated glomerular filtration rate (eGFR) have served as the cornerstone of kidney function assessment in clinical practice. While these measures remain essential for evaluating renal function, growing evidence demonstrates that they do not provide a complete picture of kidney health or future disease risk. Reliance on creatinine and eGFR alone can result in the underrecognition of early kidney damage, particularly in patients whose filtration function remains relatively preserved despite ongoing structural or vascular injury.

A significant proportion of individuals with chronic kidney disease have clinically important kidney damage even when their eGFR remains above 60 mL/min/1.73 m². In many of these patients, albuminuria is the earliest detectable abnormality and may precede measurable declines in kidney function by years. Consequently, a patient with a seemingly normal eGFR but persistent albuminuria should not be considered free of kidney disease or future risk. Rather, the presence of albumin in the urine often signals underlying pathological processes that may substantially alter both renal and cardiovascular prognosis.

Albuminuria reflects the abnormal leakage of albumin through the glomerular filtration barrier and serves as an important marker of kidney injury. The urine albumin-to-creatinine ratio (ACR) has emerged as a simple, accessible, and highly informative tool for detecting this abnormality. Numerous epidemiological and clinical studies have demonstrated that elevated urine ACR is independently associated with an increased risk of chronic kidney disease progression, cardiovascular events, heart failure, and premature mortality. Importantly, these associations persist even among individuals with preserved eGFR, highlighting the complementary information provided by albuminuria testing.

This growing body of evidence has led many experts to describe albuminuria as a “vital sign” of kidney and cardiovascular risk. The term is not intended to suggest that urine ACR should be measured as frequently as blood pressure, pulse rate, respiratory rate, or body temperature. Rather, the phrase emphasizes the clinical importance of albuminuria as a readily measurable biomarker that provides actionable information regarding a patient’s overall vascular and renal health. Just as elevated blood pressure identifies individuals at increased risk of cardiovascular complications, persistent albuminuria identifies patients who may benefit from earlier intervention to prevent kidney disease progression and reduce cardiovascular risk.

The comparison between urine ACR and low-density lipoprotein cholesterol (LDL-C) further illustrates its preventive value. LDL-C transformed cardiovascular medicine by enabling clinicians to identify elevated risk long before the development of myocardial infarction, stroke, or other major cardiovascular events. Through widespread screening and targeted interventions, LDL-C measurement became a cornerstone of preventive cardiology. Similarly, urine ACR offers an opportunity to identify kidney and cardiovascular risk at an earlier stage, often before the appearance of overt symptoms or notable reductions in kidney function. This early identification allows clinicians to implement therapies that may alter the disease trajectory and improve long-term outcomes.

However, the analogy between albuminuria and LDL-C has important limitations. LDL-C is a well-established causal factor in atherosclerotic cardiovascular disease, and lowering LDL-C directly reduces cardiovascular event rates. Albuminuria, by contrast, is a more complex biological marker. Rather than representing a single disease mechanism, it reflects the cumulative effects of multiple pathological processes occurring within the kidney and the vascular system.

Elevated urinary albumin excretion may indicate glomerular filtration barrier dysfunction, endothelial injury, intraglomerular hypertension, systemic hemodynamic stress, chronic inflammation, oxidative stress, and abnormalities in tubular albumin handling. In many cases, albuminuria also serves as a marker of generalized vascular disease affecting multiple organ systems. Consequently, albuminuria should be viewed not simply as a kidney-specific abnormality but as an indicator of broader cardiometabolic and vascular dysfunction.

This broader perspective has important implications for clinical management. The primary goal is not to react to every minor fluctuation in urine ACR, as albumin excretion can vary due to factors such as exercise, hydration status, infection, fever, and transient physiological stress. Instead, clinicians should focus on identifying persistent albuminuria through appropriate repeat testing and confirmation. Once persistent albuminuria is established, the emphasis should shift toward determining its underlying cause, assessing associated risk factors, and implementing evidence-based interventions.

Effective management may include optimization of blood pressure control, particularly through agents that target the renin-angiotensin-aldosterone system, such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. More recently, sodium-glucose cotransporter-2 inhibitors have demonstrated substantial benefits in reducing albuminuria, slowing chronic kidney disease progression, and lowering cardiovascular risk across a wide range of patient populations. Additional strategies may include glycemic control, lipid management, weight reduction, smoking cessation, dietary modification, and treatment of underlying cardiovascular risk factors.

The increasing recognition of the interconnected nature of kidney, cardiovascular, and metabolic disease has led to the emergence of the cardiovascular-kidney-metabolic framework, which emphasizes the shared pathophysiological mechanisms linking these conditions. Within this framework, albuminuria occupies a central role as both a marker of disease activity and a target for risk reduction strategies. Its presence often identifies patients who require more intensive monitoring and earlier therapeutic intervention than would be suggested by eGFR alone.

In conclusion, creatinine and eGFR remain indispensable components of kidney assessment, but they are insufficient when used in isolation. Albuminuria provides critical information about kidney injury, vascular health, and future clinical risk that cannot be captured by measures of filtration alone. A patient with preserved eGFR and persistent albuminuria should not be viewed as having normal kidney health, as their long-term renal and cardiovascular prognosis may differ substantially from what eGFR alone suggests. Recognizing albuminuria as a key risk marker and incorporating routine urine ACR testing into clinical practice can improve risk stratification, facilitate earlier intervention, and ultimately lead to better kidney and cardiovascular outcomes.

What Urine ACR Measures

The urine albumin-to-creatinine ratio estimates albumin excretion from a spot urine sample. By indexing albumin to creatinine, the test adjusts for urine concentration and is more practical than a timed urine collection. A first-morning urine sample is preferred when feasible because it reduces biologic variability, but random spot testing is acceptable for most clinical workflows.

Albuminuria becomes clinically meaningful when it is persistent. A single abnormal result should usually be repeated, especially when the value is borderline or the patient has a transient confounder.

Table 1. Mobile-Friendly Interpretation of Urine ACR

Finding	Clinical meaning
A1: <30 mg/g	Normal to mildly increased. If no other kidney abnormalities are present, this does not by itself define CKD.
A2: 30 to 300 mg/g	Moderately increased albuminuria. Repeat to confirm persistence and assess cardiovascular-kidney-metabolic risk.
A3: >300 mg/g	Severely increased albuminuria. Confirm persistence, intensify kidney-protective care when appropriate, and consider nephrology referral depending on eGFR, trajectory, hematuria, and cause.
Persistent abnormality	More clinically important than a single abnormal value. CKD generally requires abnormal kidney structure or function for at least 3 months.

Transient albuminuria can occur with urinary tract infection, fever, acute illness, marked hyperglycemia, uncontrolled hypertension, vigorous exercise, menstruation, heart failure exacerbation, and acute kidney injury. These situations should be considered before labeling a patient as having persistent CKD.

Why Albuminuria Matters

Albuminuria is increasingly recognized as more than a marker of kidney damage. It serves as both a renal biomarker and a broader indicator of systemic vascular health. The presence of albumin in the urine reflects abnormalities in the mechanisms that normally prevent marked protein loss through the kidneys and often signals underlying pathological processes affecting both the renal and cardiovascular systems. As a result, albuminuria has become a cornerstone of risk assessment in chronic kidney disease (CKD) and an important predictor of adverse cardiovascular outcomes.

Under normal physiological conditions, the kidneys retain almost all circulating albumin within the bloodstream. This function depends on the integrity of the glomerular filtration barrier, a highly specialized structure composed of several interconnected components. These include the endothelial glycocalyx, which forms a protective layer on the luminal surface of glomerular capillaries, the glomerular basement membrane that provides structural and charge-selective filtration properties, and podocytes, whose interdigitating foot processes create slit diaphragms that restrict protein passage. Beyond glomerular filtration, the proximal tubules also contribute to albumin handling through the reabsorption and degradation of small amounts of filtered protein. Injury or dysfunction at any of these levels can compromise the kidney’s ability to retain albumin, resulting in increased urinary albumin excretion.

The urine albumin-to-creatinine ratio (ACR) has become the preferred method for quantifying albuminuria in clinical practice because it provides a convenient and reliable estimate of urinary albumin excretion. Numerous studies have demonstrated a strong relationship between elevated urine ACR and the progression of chronic kidney disease. Patients with higher levels of albuminuria are more likely to experience accelerated declines in kidney function, progression to advanced CKD, and eventual kidney failure requiring dialysis or transplantation. Importantly, this association persists across a wide range of estimated glomerular filtration rate (eGFR) values. Patients with preserved filtration function may still carry substantial renal risk if significant albuminuria is present.

This understanding has fundamentally changed how chronic kidney disease is classified and managed. Modern CKD staging systems incorporate both eGFR and albuminuria because each provides distinct and complementary prognostic information. While eGFR reflects the kidney’s filtering capacity, albuminuria serves as a marker of structural kidney injury and ongoing pathological activity. Combining these parameters allows clinicians to more accurately estimate the risk of disease progression and tailor monitoring and treatment strategies accordingly.

The clinical significance of albuminuria extends well beyond nephrology. A growing body of evidence demonstrates that elevated urinary albumin excretion is a powerful predictor of cardiovascular morbidity and mortality. Even modest increases in albuminuria have been associated with higher risks of heart failure, coronary artery disease, stroke, cardiovascular death, and all-cause mortality. These associations have been observed in individuals with and without diabetes, hypertension, or established kidney disease, highlighting the broad relevance of albuminuria as a marker of systemic health.

Importantly, the relationship between albuminuria and cardiovascular disease should not be interpreted as evidence that albuminuria directly causes cardiovascular events. Rather, albuminuria is widely considered a manifestation of underlying pathophysiological processes that affect multiple organ systems simultaneously. Increased urinary albumin excretion often reflects generalized endothelial dysfunction, vascular injury, chronic inflammation, oxidative stress, neurohormonal activation, and microvascular disease. These mechanisms contribute not only to kidney injury but also to the development and progression of cardiovascular disease.

Endothelial dysfunction is particularly important in this context. The vascular endothelium plays a critical role in maintaining vascular tone, regulating inflammation, and preserving barrier function. When endothelial integrity is compromised, increased permeability can occur both within the kidneys and throughout the systemic circulation. Albuminuria may therefore represent a readily measurable manifestation of widespread vascular injury, providing insight into a patient’s overall cardiovascular risk profile.

Similarly, activation of neurohormonal systems such as the renin-angiotensin-aldosterone system and the sympathetic nervous system contributes to both albuminuria and cardiovascular disease progression. These pathways promote hypertension, inflammation, fibrosis, and adverse remodeling in the kidneys, heart, and blood vessels. As a result, albuminuria often serves as a marker of active disease processes rather than simply a consequence of established organ damage.

This distinction has important implications for clinical practice. Albuminuria should not be viewed as an isolated laboratory abnormality or a standalone treatment target. Instead, it should be interpreted as a clinically meaningful risk signal that prompts a more comprehensive evaluation of the patient. When albuminuria is detected, clinicians should consider the possibility of underlying diabetes, hypertension, cardiovascular disease, metabolic dysfunction, systemic inflammatory conditions, and other factors that may contribute to both renal and vascular injury.

A patient-centered approach requires integrating albuminuria into a broader assessment of cardiovascular and renal risk. This includes evaluating blood pressure control, glycemic status, lipid profiles, cardiovascular history, medication use, and lifestyle factors. Early identification of albuminuria provides an opportunity to implement evidence-based interventions such as renin-angiotensin system blockade, sodium-glucose cotransporter 2 inhibitors, optimized blood pressure management, and cardiovascular risk reduction strategies that can improve both kidney and cardiovascular outcomes.

In summary, albuminuria represents far more than a marker of protein leakage from the kidneys. It is a sensitive indicator of glomerular injury, a predictor of chronic kidney disease progression, and a powerful marker of systemic vascular dysfunction. Its presence reflects complex biological processes involving endothelial injury, inflammation, neurohormonal activation, and microvascular disease. For clinicians, albuminuria should be interpreted not merely as a laboratory value but as an important warning signal that warrants a comprehensive assessment of renal and cardiovascular health. Recognizing albuminuria in this broader context can facilitate earlier intervention, more accurate risk stratification, and ultimately improved patient outcomes.

Where the LDL-C Analogy Helps

The LDL-C comparison helps clinicians think preventively. Before cholesterol screening became routine, many patients were identified only after clinical events. A similar problem exists in kidney disease. If clinicians rely only on creatinine, they may identify CKD after risk has already accumulated.

Urine ACR is also useful because it can change management. In the right patient, persistent albuminuria may support initiation or optimization of renin-angiotensin system blockade, SGLT2 inhibitor therapy, finerenone, selected GLP-1 receptor agonist therapy, blood pressure intensification, lipid management, smoking cessation, and nephrology referral.

The analogy becomes misleading when it implies that ACR is identical to LDL-C as a treatment target. LDL-C lowering has a direct, graded, and extensively validated relationship with lower atherosclerotic event rates. Albuminuria reduction is associated with improved kidney outcomes and may serve as a useful surrogate endpoint in selected settings, but the strength of that relationship depends on the population, intervention, baseline risk, and clinical endpoint.

A more accurate statement is this: urine ACR is not the new LDL-C biologically, but it may become LDL-C-like in clinical workflow. It is a simple test that identifies risk early and can direct preventive therapy.

Who Should Be Tested

Routine urine ACR testing is most strongly supported in patients with diabetes, hypertension, established CKD, heart failure, established ASCVD, obesity with metabolic risk factors, family history of kidney disease, or other CKD risk factors. In these groups, urine ACR and eGFR should usually be assessed together.

Universal screening of every asymptomatic adult is a separate question. The evidence is not as strong for low-risk adults without diabetes, hypertension, CKD, or cardiovascular-kidney-metabolic risk factors. For this reason, the strongest practical recommendation is targeted systematic testing in high-risk populations rather than indiscriminate universal screening.

Table 2. When to Order Urine ACR

Clinical setting	Practical approach
Type 2 diabetes	Check urine ACR and eGFR at diagnosis and at least annually. Monitor more often when CKD is present.
Type 1 diabetes	Begin screening after several years of disease duration, then monitor at least annually when indicated.
Hypertension	Test when CKD risk is present, especially with long-standing hypertension, resistant hypertension, diabetes, or cardiovascular disease.
Established CKD	Use urine ACR with eGFR to stage risk, monitor progression, and guide therapy.
Heart failure or ASCVD	Consider urine ACR as part of broader cardiovascular-kidney-metabolic risk assessment.
Low-risk asymptomatic adult	Routine universal testing remains less clearly supported. Use clinical judgment.

How to Confirm and Interpret an Abnormal Result

An abnormal urine ACR should lead to confirmation, not panic. If the patient is acutely ill, has a urinary tract infection, recently exercised vigorously, is menstruating, or has severe hyperglycemia or uncontrolled blood pressure, repeat testing after stabilization is usually more informative.

A urinalysis is often useful when albuminuria is newly identified. Hematuria, casts, or active sediment may suggest a glomerular process that requires a different diagnostic pathway. A medication review is also important. Nonsteroidal anti-inflammatory drugs, recent contrast exposure, calcineurin inhibitors, lithium, certain anticancer therapies, and other nephrotoxic agents may contribute to kidney injury.

Interpretation should include four questions:

Question	Why it matters
Is the albuminuria persistent?	Persistent abnormality carries more prognostic weight than a single abnormal value.
What is the eGFR?	eGFR and ACR together define CKD risk more accurately than either alone.
Is there hematuria or active sediment?	These findings may suggest glomerulonephritis or another nonmetabolic kidney disease.
Is there a treatable driver?	Diabetes, hypertension, heart failure, obesity, medications, and acute illness can all influence ACR.

Therapeutic Implications

The clinical importance of albuminuria has increased because abnormal results can trigger therapies that reduce kidney and cardiovascular events.

Renin-Angiotensin System Blockade

ACE inhibitors and ARBs remain foundational for many patients with albuminuric CKD, particularly when diabetes or hypertension is present. They reduce intraglomerular pressure and can lower albuminuria. When indicated, they should generally be titrated to the highest tolerated evidence-based dose.

Dual ACE inhibitor plus ARB therapy should be avoided. Combining renin-angiotensin system agents increases the risk of hyperkalemia, hypotension, and kidney function decline without providing adequate outcome benefit.

Monitoring is essential. Serum creatinine and potassium should be checked after initiation or dose escalation. A modest early creatinine rise can be hemodynamic and acceptable, but larger or progressive increases require reassessment.

SGLT2 Inhibitors

SGLT2 inhibitors have changed CKD treatment. Their kidney and cardiovascular benefits are not limited to glucose lowering. In eligible patients with CKD, these agents reduce risk of kidney disease progression and heart failure outcomes.

Before initiation, clinicians should assess eGFR, volume status, diuretic use, ketoacidosis risk, genital mycotic infection history, and perioperative plans. Patients should be counseled about sick-day management. Temporary interruption is appropriate before major surgery or prolonged fasting and during serious acute illness.

Finerenone

Finerenone is a nonsteroidal mineralocorticoid receptor antagonist with kidney and cardiovascular outcome data in patients with CKD associated with type 2 diabetes. It should not be treated as interchangeable with spironolactone. Spironolactone is useful for resistant hypertension and heart failure indications, and it can reduce albuminuria, but finerenone has dedicated outcome data in diabetic CKD populations.

Potassium monitoring is central. Finerenone can cause hyperkalemia, especially in patients with lower eGFR or concomitant potassium-raising therapies. Strong CYP3A4 inhibitors are contraindicated.

GLP-1 Receptor Agonist Therapy

Semaglutide has kidney-outcome evidence in adults with type 2 diabetes and CKD. This should be framed as drug-specific evidence rather than a blanket assumption for every GLP-1 receptor agonist. In appropriate patients, semaglutide may be considered alongside glycemic control, weight, ASCVD risk, kidney risk, tolerability, and labeling considerations.

Clinicians should monitor for gastrointestinal intolerance, dehydration, acute kidney injury risk during severe vomiting or diarrhea, gallbladder disease, hypoglycemia when combined with insulin or insulin secretagogues, and product-specific contraindications.

Table 3. Albuminuria-Driven Therapy Review

Therapy	Clinician-facing safety points
ACE inhibitor or ARB	Check creatinine and potassium after initiation or titration. Avoid pregnancy exposure. Avoid dual ACE inhibitor plus ARB therapy.
SGLT2 inhibitor	Assess eGFR and volume status. Counsel on genital mycotic infections, ketoacidosis symptoms, sick-day holds, and perioperative interruption.
Finerenone	Use in appropriate CKD associated with type 2 diabetes. Check potassium and eGFR before and after initiation. Avoid strong CYP3A4 inhibitors.
Semaglutide	Consider in appropriate type 2 diabetes with CKD. Monitor gastrointestinal effects, dehydration-related AKI risk, gallbladder disease, and hypoglycemia risk with insulin or sulfonylureas.

Monitoring Treatment Response

The urine albumin-to-creatinine ratio (ACR) is a cornerstone biomarker in the evaluation and management of chronic kidney disease (CKD), particularly in patients with diabetes, hypertension, and other conditions associated with kidney damage. Beyond its diagnostic value, urine ACR serves as an important tool for monitoring treatment response and assessing ongoing kidney and cardiovascular risk. However, its interpretation requires clinical context and should be approached with an understanding of its strengths and limitations.

A reduction in albuminuria following the initiation of therapy is generally considered a favorable sign. Numerous studies have demonstrated that decreases in urinary albumin excretion are associated with slower progression of chronic kidney disease and a lower risk of cardiovascular events. Consequently, therapies such as renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, mineralocorticoid receptor antagonists, and optimized blood pressure and glycemic management are often evaluated in part by their ability to reduce albuminuria.

Nevertheless, clinicians should avoid interpreting urine ACR values too rigidly. While a sustained reduction in albuminuria is reassuring, it should not be viewed as the sole indicator of therapeutic success. Kidney disease progression is multifactorial, and improvements in albuminuria do not necessarily guarantee preservation of renal function or elimination of cardiovascular risk. Similarly, persistent albuminuria despite optimized treatment identifies patients who remain at elevated risk for adverse kidney and cardiovascular outcomes. These individuals may require further risk factor modification, closer monitoring, and consideration of additional therapeutic interventions.

Changes in urine ACR should always be interpreted within the broader clinical picture. Significant increases in albuminuria warrant careful clinical review, particularly when the change is abrupt or unexpected. A sudden rise in ACR may reflect poorly controlled hypertension, worsening hyperglycemia, medication nonadherence, acute illness, heart failure exacerbation, systemic infection, or volume overload. It may also signal the development of new glomerular pathology, progression of underlying kidney disease, or drug related nephrotoxicity. Identifying the underlying cause is essential because management strategies differ substantially depending on the clinical context.

Conversely, declining albuminuria is generally encouraging and often indicates a favorable response to treatment. However, clinicians should avoid relying exclusively on albuminuria reduction as a marker of success. Comprehensive monitoring should continue to include estimated glomerular filtration rate (eGFR), serum potassium levels, blood pressure control, glycemic status, and overall cardiovascular risk assessment. These parameters provide complementary information regarding kidney function, treatment safety, and long term prognosis.

Perhaps the most important principle in urine ACR interpretation is the emphasis on trends rather than isolated measurements. A single ACR value can provide useful diagnostic information, but serial measurements offer far greater clinical insight. Longitudinal assessment allows clinicians to distinguish meaningful changes from normal biological variation, identify emerging patterns of disease progression, and evaluate the sustained effects of therapeutic interventions. In routine practice, trend based interpretation often provides a more accurate reflection of kidney health than any individual result.

Limitations of Urine ACR

Despite its substantial clinical utility, urine ACR is not a perfect biomarker. Several physiological and pathological factors can influence results, creating variability that may complicate interpretation. Albumin excretion naturally fluctuates over time, and values can be affected by hydration status, physical activity, body position, acute illness, fever, emotional stress, and recent dietary intake. Urinary tract infections and other inflammatory conditions may also transiently increase urinary albumin excretion, potentially leading to misleading results if measurements are obtained during periods of acute illness.

The creatinine component of the ratio introduces additional complexity. Because urine ACR is normalized to urinary creatinine concentration, factors affecting creatinine production can influence the final value. Individuals with low muscle mass, such as older adults, frail patients, or those with muscle wasting disorders, may have lower urinary creatinine excretion, resulting in an artificially elevated ACR. In contrast, highly muscular individuals may exhibit higher urinary creatinine levels, potentially lowering the ratio and masking clinically relevant albuminuria. These physiological differences should be considered when interpreting results, particularly in populations at the extremes of body composition.

Another important limitation is that albuminuria does not capture all forms of kidney disease. While elevated urine ACR is a sensitive marker of glomerular injury and endothelial dysfunction, some patients experience progressive kidney function decline with minimal or no detectable albuminuria. This phenomenon is particularly relevant in conditions such as tubulointerstitial disease, obstructive uropathy, ischemic nephropathy, vascular kidney disease, medication induced nephrotoxicity, and certain inherited renal disorders. In these situations, kidney damage may progress despite normal or only mildly elevated urinary albumin levels.

For this reason, a normal urine ACR should never be interpreted as definitive evidence of kidney health. If eGFR is declining, urinary sediment is abnormal, imaging studies reveal structural abnormalities, or clinical suspicion remains high, further evaluation is warranted regardless of albuminuria status. Reliance on ACR alone may result in missed diagnoses and delayed intervention in patients with nonproteinuric kidney disease.

Albuminuria Is a Marker, Not a Diagnosis

A critical concept in clinical nephrology is that albuminuria represents a finding rather than a diagnosis. The presence of elevated urinary albumin identifies kidney injury and increased cardiovascular risk, but it does not establish the underlying cause. Determining the etiology remains an essential component of patient evaluation and management.

Common causes of albuminuria include diabetic kidney disease, hypertensive nephrosclerosis, obesity related glomerulopathy, primary glomerular diseases such as IgA nephropathy and focal segmental glomerulosclerosis, and systemic disorders affecting the kidneys. Albuminuria may also occur in the setting of heart failure due to renal venous congestion and hemodynamic alterations. Certain medications, toxins, infections, autoimmune diseases, and genetic conditions can similarly contribute to increased urinary albumin excretion.

Accurate diagnosis requires integration of urine ACR results with clinical history, physical examination findings, laboratory data, imaging studies, and, in selected cases, kidney biopsy. Understanding the underlying disease process is essential because prognosis, treatment strategies, and monitoring requirements vary considerably among different causes of albuminuria.

Clinical Perspective

Urine ACR remains one of the most valuable tools available for assessing kidney damage, stratifying risk, and monitoring treatment response. Its ability to predict both renal and cardiovascular outcomes has made it a central component of modern kidney disease management. However, its greatest value emerges when interpreted thoughtfully within a broader clinical framework. Clinicians should focus on longitudinal trends rather than isolated values, recognize the biological and technical factors that influence measurements, and remember that albuminuria is a marker of disease rather than a diagnosis in itself. When combined with eGFR, clinical assessment, and appropriate diagnostic evaluation, urine ACR provides powerful insights that support more accurate risk assessment, earlier intervention, and improved long term patient outcomes.

Practical Clinical Workflow

A practical workflow is simple.

Order urine ACR with serum creatinine and eGFR in high-risk patients. If urine ACR is normal, repeat according to the patient’s risk category. If it is abnormal, confirm persistence and assess for confounders. If albuminuria persists, classify CKD risk using both eGFR and ACR. Then optimize therapy, address cardiovascular-kidney-metabolic risk factors, and determine whether nephrology referral is appropriate.

Table 4. Mobile-Friendly Action Checklist

Step	Action
1	Order urine ACR and eGFR together in high-risk patients.
2	Repeat abnormal ACR when transient causes are possible.
3	Check urinalysis if albuminuria is new, marked, or unexplained.
4	Optimize blood pressure, glycemic management, lipid therapy, and smoking cessation.
5	Consider ACE inhibitor or ARB, SGLT2 inhibitor, finerenone, or semaglutide when indicated.
6	Monitor potassium, creatinine, eGFR, volume status, and adverse effects after therapy changes.
7	Refer to nephrology for uncertain cause, rapid progression, severe albuminuria, active sediment, or advanced CKD.

References

American Diabetes Association Professional Practice Committee for Diabetes*. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan 1;49(Supplement_1):S246-S260. doi: 10.2337/dc26-S011.

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. PMID: 33264825.

Chronic Kidney Disease Prognosis Consortium; Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010 Jun 12;375(9731):2073-2081. doi: 10.1016/S0140-6736(10)60674-5. PMID: 20483451.

de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022 Nov;102(5):974-989. doi: 10.1016/j.kint.2022.08.012. PMID: 36202661

The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. PMID: 36331190.

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144. PMID: 28444290.

Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, et al.; Chronic Kidney Disease Epidemiology Collaboration. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. doi: 10.1016/S2213-8587(18)30314-0. PMID: 30635226.

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al.; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. PMID: 32970396.

Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans ROB, Janssen WMT, Grobbee DE, de Jong PE. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.Circulation. 2002 Oct 1;106(14):1777-1782. doi: 10.1161/01.CIR.0000031732.78052.81. PMID: 12356629.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018. PMID: 38490803.

Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al.; CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015 Jul;3(7):514-525. doi: 10.1016/S2213-8587(15)00040-6. PMID: 26028594.

Ndumele CE, Rodriguez F, Dixon DL, Khan SS, Mukherjee D, Bajaj M, et al. 2026 AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Published online June 9, 2026. doi: 10.1161/CIR.0000000000001453. PMID: 42265997.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al.; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. PMID: 30990260.

Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al.; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. PMID: 38785209.

Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al.; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. PMID: 34449181.

DailyMed prescribing information for empagliflozin, dapagliflozin, finerenone, and semaglutide – Accessed: June 2026.